PT - JOURNAL ARTICLE AU - Andrejko, Kristin L. AU - Myers, Jennifer F. AU - Openshaw, John AU - Fukui, Nozomi AU - Li, Sophia AU - Watt, James P. AU - Murray, Erin L. AU - Hoover, Cora AU - Lewnard, Joseph A. AU - Jain, Seema AU - Pry, Jake M. AU - , TI - Receipt of COVID-19 and seasonal influenza vaccines in California (USA) during the 2021-2022 influenza season AID - 10.1101/2022.10.21.22281343 DP - 2022 Jan 01 TA - medRxiv PG - 2022.10.21.22281343 4099 - http://medrxiv.org/content/early/2022/10/22/2022.10.21.22281343.short 4100 - http://medrxiv.org/content/early/2022/10/22/2022.10.21.22281343.full AB - Background Despite lower circulation of influenza virus throughout 2020–2022 during the COVID-19 pandemic, seasonal influenza vaccination has remained a primary tool to reduce influenza-associated illness and death. The relationship between the decision to receive a COVID-19 vaccine and/or an influenza vaccine is not well understood.Methods We assessed predictors of receipt of 2021–2022 influenza vaccine in a secondary analysis of data from a case-control study enrolling individuals who received SARS-CoV-2 testing. We used mixed effects logistic regression to estimate factors associated with receipt of seasonal influenza vaccine. We also constructed multinomial adjusted marginal probability models of being vaccinated for COVID-19 only, seasonal influenza only, or both as compared with receipt of neither vaccination.Results Among 1261 eligible participants recruited between 22 October 2021 – 22 June 2022, 43% (545) were vaccinated with both seasonal influenza vaccine and ≥1 dose of a COVID-19 vaccine, 34% (426) received ≥1 dose of a COVID-19 vaccine only, 4% (49) received seasonal influenza vaccine only, and 19% (241) received neither vaccine. Receipt of ≥1 COVID-19 vaccine dose was associated with seasonal influenza vaccination (adjusted odds ratio [aOR]: 3.72; 95% confidence interval [CI]: 2.15–6.43); this association was stronger among participants receiving ≥1 COVID-19 booster dose (aOR=16.50 [10.10– 26.97]). Compared with participants testing negative for SARS-CoV-2 infection, participants testing positive had lower odds of receipt of 2021-2022 seasonal influenza vaccine (aOR=0.64 [0.50–0.82]).Conclusions Recipients of a COVID-19 vaccine were more likely to receive seasonal influenza vaccine during the 2021–2022 season. Factors associated with individuals’ likelihood of receiving COVID-19 and seasonal influenza vaccines will be important to account for in future studies of vaccine effectiveness against both conditions. Participants who tested positive for SARS-CoV-2 in our sample were less likely to have received seasonal influenza vaccine, suggesting an opportunity to offer influenza vaccination before or after a COVID-19 diagnosis.Competing Interest StatementJ.A.L. discloses receipt of grants and honoraria from Pfizer, Inc, outside the submitted work. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.Funding StatementAuthors J.M.P., J.O., J.F.M., and the California COVID-19 case-control interviewer team were supported by a grant from the National Institutes of Health (NIH)/CDC Epidemiology and Laboratory Capacity for Infectious Disease (ELC), grant number 5-NU50CK000539 program of the US Centers for Disease Control and Prevention (program number 0187.0150)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the State of California, Health and Human Services Agency, Committee for the Protection of Human Subjects (Project Number: 2021-034).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAuthors are not authorized to share data.